Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was terminated on 01-Aug-2011 due to very low potential to enroll planned number of patients or any sufficient number of patients for complete statistical analyses. This study is not being terminated because of safety or efficacy concerns.
Age
18–60
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Postmenopausal females.
Patients who have had surgical treatment for histological confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.
Patients who are disease-free after 2 or 3 years of adjuvant tamoxifen treatment.
Patients whose tumour was estrogen receptor positive (ER+).
Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
You may not be if
Patients for whom Aromasin® treatment is contraindicated (see SPC).
Presence of metastasis or a contra lateral tumour.
Other adjuvant endocrine therapy.
Another concomitant antineoplastic treatment.
Participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.
Clareo Health | Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
